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Background: Factors associated with disease progression in dogs with preclinical (stage B)
degenerative mitral valve disease (DMVD) have not been evaluated previously in primary care
veterinary practice.
Objectives: To evaluate whether plasma cardiac biomarkers, clinical signs, and physical examina-
tion findings are associated with clinical progression (reaching the composite endpoint of initia-
tion of treatment with a potent diuretic or cardiac death) in dogs presumed to have stage
B DMVD.
Animals: Six-hundred and eighty-four dogs diagnosed with DMVD recruited from 73 primary
care practices in the United Kingdom. Dogs were not receiving potent diuretics at recruitment.
Methods: Prospective cohort study design. Primary care veterinarians recorded the presence or
absence of clinical signs and physical examination findings. Baseline plasma N-terminal pro B-
type natriuretic peptide (NT-proBNP) and cardiac troponin I were measured. Cox regression
models measured associations between risk factor variables and clinical progression. Flexible
parametric models generated predicted probabilities of reaching the composite endpoint for
dogs with different combinations of prognostic risk factor variables.
Results: Plasma NT-proBNP, heart rate, heart murmur intensity, presence of a cough, being a
Cavalier King Charles Spaniel, and being prescribed pimobendan were associated with clinical
progression to initiation of treatment with a potent diuretic or cardiac-related death.
Conclusions and Clinical Importance: Dogs with stage B DMVD identified as having a high risk
of disease progression might benefit from more frequent monitoring or further diagnostic evalu-
ation. The prognostic factors identified could facilitate risk stratification of dogs presenting with
preclinical DMVD.
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1 | INTRODUCTION
Dogs with degenerative mitral valve disease (DMVD) are on a diverse
spectrum of disease severity. The American College of Veterinary
Internal Medicine consensus statement, heart disease severity grading
scheme (ACVIM-HD) describes 4 stages of heart disease and failure in
Abbreviations: ACVIM-HD, American College of Veterinary Internal Medicine
consensus statement, heart disease severity grading scheme; bpm, beats per
minute; CHF, congestive heart failure; CKCS, Cavalier King Charles Spaniel;
cTnI, cardiac troponin I; DMVD, degenerative mitral valve disease; EPIC, Evalua-
tion of Pimobendan In dogs with Cardiomegaly; EPR, electronic patient record;
HR, hazard ratio; IQR, interquartile range; NT-proBNP, N-terminal pro B-type
natriuretic peptide; PH, proportional hazards; SD, standard deviation; VetCom-
pass, Veterinary Companion Animal Surveillance System.
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dogs with DMVD.1 Stage A describes dogs at high risk of DMVD that
are yet to develop structural heart disease (eg, dogs of breeds predis-
posed to DMVD that do not have heart murmurs). Stage B denotes
the preclinical stages of DMVD, whereby dogs have heart murmurs as
a result of mitral regurgitation but no current or previous history of
congestive heart failure (CHF). Stages C and D describe dogs with
DMVD that has progressed to CHF. Until recently, there has been no
strong evidence for the benefit of treatment in dogs with stage B
DMVD. Distinguishing between ACVIM-HD stages B1 (preclinical
DMVD with a normal heart size) and B2 (preclinical DMVD with
cardiac chamber enlargement), therefore, might not have altered the
management of these cases. However, because the EPIC study
reported the benefit of administering pimobendan to dogs with
echocardiographic and radiographic evidence of advanced stage
B2 disease, there is greater interest and clinical merit in identifying
dogs with more advanced preclinical DMVD.2
Previous observational studies and randomized controlled trials
have evaluated factors associated with disease progression in dogs
with stage B DMVD.2–8 Natriuretic peptides,3,4,6 radiographic and
echocardiographic measurements,2–5,7 presenting signs and physical
examination findings,2,5–8 age,7 systolic arterial blood pressure,2 and
pimobendan treatment2 have been reported to be associated with
outcome in dogs with preclinical DMVD. However, the samples of
dogs included in these studies were restricted to those attending
teaching or referral hospitals or a single breed. These samples might
be poorly representative of the spectrum of dogs with preclinical
DMVD attending primary care veterinary practice. Furthermore, prog-
nostic factors measured by specialist veterinary cardiologists might
not be clinically useful in primary care practice, where the level of
expertise and availability of equipment required to obtain these mea-
surements might not match those found in referral centers.9 Prognos-
tic factors that can be readily measured in the primary care setting
could help first opinion veterinarians assess the likely disease severity
in dogs with preclinical DMVD. The ability to do so could aid prognos-
tication when evaluating the likely outcome for a dog and identify
those dogs that might benefit most from frequent monitoring, diag-
nostic imaging, or evaluation by a veterinary cardiologist.
Our aim was to prospectively follow dogs presumed to have stage
B DMVD and to evaluate whether key measurements were associated
with disease progression in the UK primary care setting.
Our objectives were to:
• Determine whether plasma cardiac biomarker concentrations are
associated with clinical progression to initiation of treatment with
a potent diuretic or cardiac-related death in dogs with presumed
stage B DMVD attending primary care veterinary practices.
• Evaluate whether physical examination findings and the presence
or absence of clinical signs provide additional prognostic informa-
tion to risk stratify affected animals.
2 | MATERIALS AND METHODS
A prospective cohort design was used to evaluate factors associated
with disease progression in dogs presumed to have stage B DMVD
attending UK primary care veterinary practices. Animals included were
a subset of a heterogeneous sample of dogs with any stage of DMVD
described previously.10 Dogs diagnosed with DMVD were recruited
to the study by veterinarians during episodes of care or by letters
inviting participation. Cases were defined as dogs with a diagnosis of
DMVD attending collaborating primary care practices in the United
Kingdom. Diagnosis could be presumptive and based on clinical find-
ings alone (left apical systolic heart murmur in a dog of typical signal-
ment). Confirmation of the diagnosis by echocardiography was not an
inclusion criterion. Participating practices were provided with informa-
tion on typical presentation and risk factors for DMVD to improve the
accuracy of presumptive diagnoses. Age and breed restrictions were
not imposed in order to maximize the extent to which our results
could be generalized to the wider population of dogs with DMVD
attending primary care practice. The subset included in our study was
restricted to dogs diagnosed with presumed DMVD that did not
receive a potent diuretic (furosemide, torasemide, and amiloride with
hydrochlorothiazide) before or within 14 days of recruitment to the
study. These dogs herein are referred to as having presumed ACVIM-
HD classification stage B DMVD (dogs that have a heart murmur typi-
cal of mitral regurgitation, but no history of clinical signs caused by
CHF1). Dogs starting diuretics within 14 days of recruitment were not
included to avoid erroneously classifying dogs with preexisting CHF
as stage B cases and to limit misclassification bias arising from veteri-
narians starting diuretic treatment based on the results of the findings
at the initial visit and cardiac biomarker assay results.
The composite endpoint was reached when treatment with a
potent diuretic was initiated or death attributed to cardiac disease
was documented. Although thoracic radiography generally is consid-
ered to be the clinical gold standard for diagnosing CHF,11 it was not
consistently performed, and starting treatment with a potent diuretic
was used as a proxy for clinical progression to stage C DMVD. This
article has been approved by the Royal Veterinary College's publica-
tions approval system to comply with Good Research Practice Policy
on Publications (manuscript number PPS_01758).
To recruit a dog to the study, veterinarians obtained written
owner consent, recorded clinical data on a specially designed form,
and collected a 2 mL blood sample to measure circulating plasma
N-terminal pro B-type natriuretic peptide (NT-proBNP) and cardiac
troponin I (cTnI) concentrations. Descriptors of each heart murmur
intensity grade were provided in an effort to standardize how veteri-
narians assessed this variable and thus improve interobserver reliabil-
ity. Plasma NT-proBNP was measured using a second generation
ELISA test (Cardiopet® proBNP) and cTnI was measured using a 2-site
immunoenzymatic sandwich assay (Beckman Access 2 Troponin assay)
at a commercial laboratory (IDEXX laboratories, Wetherby, The
United Kingdom). Electronic patient records (EPRs) for recruited cases
either were uploaded to the Veterinary Companion Animal Surveil-
lance System (VetCompass) database,12 or shared by email, post, or
facsimile. Date of birth, breed, sex, neuter status, and body weight
were extracted from the EPRs and entered into a relational database
(Access 2010, Microsoft Corporation, Redmond, Washington). The
diagnostic tests and therapeutic interventions used to investigate and
treat the dogs' heart disease also were extracted. Any documented
comorbidities and whether the dog was insured also were extracted.
2 MATTIN ET AL.
The date, modality (euthanasia versus unassisted), and cause of
death were identified where applicable. Cardiac-related death was
defined as spontaneous death or euthanasia primarily because of clinical
signs consistent with heart disease or sudden death. Sudden death
described the unexpected natural death, without evidence of dyspnea,
in a dog with no history or indication of another condition that could
have caused death. If a dog was not reported to have died because of
its heart disease or started diuretic treatment, it was censored on the
date it was last known to be alive or the date of noncardiac death. Dogs
prescribed furosemide to treat noncardiac conditions and dogs thought
to have developed CHF because of doxorubicin toxicity also were cen-
sored. If potent diuretics were prescribed and then discontinued without
any adverse effects during the follow-up period, dogs were not classified
as having reached the endpoint because administering potent diuretics
was considered essential for preserving life in dogs with stage C and D
DMVD.1,13 The time of entry into the study was the date of recruit-
ment. Analysis time ended on the date diuretic treatment was initiated,
the date the dog died because of its cardiac disease (if diuretics were
not prescribed), or on the date of censoring.
2.1 | Statistical methods
Data were exported from the database to spreadsheets for cleaning
and checking (Excel 2010, Microsoft Corporation). Statistical analyses
were undertaken by commercially available software (Stata version
14.1, Stata Corporation, Texas).
2.1.1 | Descriptive statistics
Continuous data were assessed graphically for normality and pre-
sented as mean and SD or median and interquartile range (IQR) as
appropriate. For categorical variables, the number and percentage
within each category were presented. For time-to-event analyses, the
median time at risk was defined as the median time from recruitment
until starting treatment with a potent diuretic, experiencing cardiac-
related death or censoring.
2.1.2 | Cox proportional hazard and flexible parametric
models
The following explanatory (risk factor) variables were evaluated in the
time-to-event analyses: age (years), body weight (kg), sex, neuter sta-
tus, breed, evidence of insurance, plasma NT-proBNP concentration,
plasma cTnI concentration, presence or absence of cough, dyspnea
and exercise intolerance, heart rhythm, heart rate (beats per minute
[bpm]), heart murmur intensity, current cardiac treatments, and
comorbidities grouped into disorder categories. Plasma concentrations
of the cardiac biomarkers and observations recorded on the data col-
lection form (presence or absence of clinical signs and physical exami-
nation findings) were explanatory variables of a priori interest. The
cardiac biomarker data were highly skewed, with many results below
the lower limit of detection, and thus these variables were included as
categorical variables. Other continuous variables were retained as
untransformed or log transformed variables if linear associations with
the outcome were identified by likelihood ratio tests. If insufficient
evidence for a linear association was present, continuous data were
evaluated as categorical variables. Treatment variables related to
whether dogs received the following cardiac medications at the time
of recruitment: pimobendan - yes/no; angiotensin converting enzyme
(ACE) inhibitors - yes/no; and spironolactone - yes/no. Pairwise corre-
lations among all explanatory variables were assessed to identify
potential collinearity.14
Univariable Cox proportional hazard models evaluated associations
between each explanatory variable and clinical progression to initiation
of treatment with a potent diuretic or cardiac-related death. Explanatory
variables significant at the 20% level in the univariable analysis were
evaluated in the multivariable models.14 Manual backward stepwise
elimination model construction was used to identify variables with an
independent association with the outcome (5% significance level). Each
eliminated variable subsequently was added back into the model to
check for confounding by observing the magnitude of changes in the
model coefficients. Interactions between explanatory variables included
in final multivariable models were evaluated. Veterinary clinic was eval-
uated as a shared frailty term. The proportional hazards (PH) assumption
was evaluated by log-cumulative hazard and Kaplan-Meier Cox plots
and the Schoenfeld residuals test of the assumption of PH.14,15 The
predictive ability of the models was evaluated by Harrell's C concor-
dance statistic.14 Martingale residuals were used to assess the func-
tional form of the relationship between continuous variables and
outcome.15 To identify outliers and individuals with disproportionate
influence, deviance residuals and likelihood displacements measures
were plotted, respectively.14,15
Royston-Parmar flexible parametric models were used to predict
survival probabilities and explore alternative approaches to modeling
time-dependent effects (eg, where hazard ratios [HRs] for explanatory
variables changed over time and did not meet the PH assumption).16–18
Flexible parametric model selection was directed by model fit, which
was assessed by graphical examination of different parametric distribu-
tions, the Akaike information criterion, and Bayesian information crite-
rion.17 Continuous variables were categorized in the multivariable
parametric model for ease of interpretation and risk stratification.
Selection of explanatory variables was as described for the Cox regres-
sion models, although variables dependent on diagnostic imaging (eg,
pimobendan administration) were excluded as the flexible parametric
model was developed to evaluate whether dogs could be risk stratified
using data routinely obtained from taking a history, performing a physi-
cal examination, and measuring cardiac biomarker concentrations. Clus-
tering within veterinary practices was not evaluated because shared
frailty terms cannot be included in flexible parametric models. Forward
selection was used to identify whether explanatory variables included
in the multivariable model had time-dependent effects.17 After specifi-
cation of the multivariable model, predicted survival probabilities (per-
centage of dogs not reaching the composite endpoint of initiation of
diuretic treatment or cardiac-related death) at 1-year follow-up were
estimated for different combinations of explanatory variable values in
the model.16,18
2.1.3 | Sample size calculation
A priori sample size calculations estimated that approximately
100 events would be required to detect a HR of 2 for a variable to
which 20% of individuals were exposed, at a confidence level of
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95% and power of 80%. Using data derived from the VetCompass
database (data not shown), it was estimated that 650-700 dogs
would need to be recruited to the study for over an 18-month
accrual period and a minimum 6 months follow-up, assuming a 10%
loss to follow-up.19
3 | RESULTS
3.1 | Study population
Six-hundred and eighty-four dogs presumptively diagnosed with
DMVD that did not receive a potent diuretic before or within 14 days
after recruitment were included in the study. The breed most fre-
quently recruited was the Cavalier King Charles Spaniel (CKCS;
n = 231, 33.9%). The mean age at recruitment was 9.3 years (SD,
3.1 years) and the median body weight was 10.5 kg (IQR, 8.1-14.9 kg).
Three-hundred and seventy (54.3%) dogs were male (Table 1). The
median plasma concentration of NT-proBNP was 600 pmol/L (IQR,
324-1141 pmol/L) and the median plasma concentration of cTnI was
0.02 ng/mL (IQR, 0.01-0.03 ng/mL).
Five dogs were excluded from the time-to-event analysis because
no follow-up data were available. For the 679 dogs included, the total
analysis time was 9163 months. Median time at risk was 13.26 months
(range, 0.07-30.74 months). One hundred and forty-three (21.1%) dogs
reached the composite endpoint. The majority of dogs reaching an end-
point started treatment with a potent diuretic (n = 123, 86.0%). Twenty
dogs died because of their heart disease without starting diuretic treat-
ment (12 were euthanized and 8 died spontaneously).
3.2 | Prognostic risk factors for dogs with presumed
stage B DMVD
3.2.1 | Cox regression analysis for variables associated
with progression to initiation of potent diuretic treatment or
cardiac death in dogs with presumed stage B DMVD
The following explanatory variables had some evidence of an associ-
ation (P < .2) with the outcome and were evaluated in multivariable
Cox regression models: age, body weight, breed, insurance status,
plasma NT-proBNP, plasma cTnI, presence of cough or dyspnea,
heart rhythm, heart rate, heart murmur intensity, administration of
pimobendan, administration of an ACE inhibitor, administration of
spironolactone, and having a musculoskeletal disorder. In the multi-
variable model, higher concentrations of plasma NT-proBNP, pres-
ence of cough, higher heart murmur intensities and heart rates,
receiving pimobendan, and being a CKCS were independently asso-
ciated with clinical progression (Table 2). Variables included in the
final multivariable model also had strong associations (P < .001) with
the outcome in univariable analysis. The Schoenfeld residuals test
was statistically significant, suggesting that the PH assumption was
violated. Plasma NT-proBNP was identified as having a time-
dependent effect (P < .001). The magnitude of the HR between the
highest and lowest categories of the biomarker decreased with time
after sampling (ie, there was a weakening of the association between
NT-proBNP and the outcome over time). Veterinary clinic was not
included in the final model because clustering was not significant.
Harrell's C concordance statistic (0.79) suggested good model dis-
crimination. Martingale residuals supported that heart rate could be
included as an untransformed linear variable. When individuals with
the largest deviance and influence were excluded from the model,
the HRs changed, but the direction of associations and conclusions
remained for all variables.
TABLE 1 Descriptive statistics for 684 dogs with presumed stage B
degenerative mitral valve disease (DMVD) attending primary care
veterinary practices in the United Kingdom
Variable Category
Number (%),
mean (SD),
median (IQR)
Missing
values, n (%)
Breed CKCS 231 (33.9) 3 (0.4)
Crossbred 104 (15.3)
Jack Russell
Terrier
41 (6.0)
Shih Tzu 25 (3.7)
Cocker Spaniel 20 (2.9)
Border Collie 20 (2.9)
King Charles
Spaniel
19 (2.8)
Chihuahua 17 (2.5)
Yorkshire Terrier 17 (2.5)
Other purebred 187 (27.5)
Age (years) Mean (SD) 9.3 (3.1) 3 (0.4)
Sex/neuter
status
MN 232 (34.0) 2 (0.3)
ME 138 (20.2)
FN 251 (36.8)
FE 61 (8.9)
Bodyweight (kg) Median (IQR) 10.5 (8.1-14.9) 37 (5.4)
Plasma
NT-proBNP
(pmol/L)
Median (IQR) 600 (324-1141) 6 (0.9)
Plasma cTnI
(ng/mL)
Median (IQR) 0.02 (0.01-0.03) 5 (0.7)
Cough No 486 (73.6) 24 (3.5)
Yes 174 (26.4)
Dyspnea No 601 (93.2) 39 (5.7)
Yes 44 (6.8)
Exercise
intolerance
No 503 (77.9) 38 (5.6)
Yes 143 (22.1)
Heart rhythm Sinus arrhythmia 174 (27.9) 61 (8.9)
Sinus rhythm 422 (67.7)
Other (non-sinus)
arrhythmia
27 (4.3)
Heart rate (bpm) Mean (SD) 119 (23.1) 37 (5.4)
Heart murmur
intensity
Soft (grade I/II) 256 (38.3) 15 (2.2)
Moderate (III) 230 (34.4)
Loud (IV) 142 (21.2)
Thrilling (V/VI) 41 (6.1)
Abbreviations: bpm, beats per minute; CKCS, Cavalier King Charles Span-
iel; cTnI, cardiac troponin I; FE, female, entire; FN, female, neutered; IQR,
interquartile range; NT-proBNP, N-terminal pro B-type natriuretic peptide;
ME, male, entire; MN, male, neutered.
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3.2.2 | Multivariable flexible parametric proportional
hazards model: Factors associated with progression to
initiation of potent diuretic treatment or cardiac death in
dogs with presumed stage B DMVD
The flexible parametric model that best fit the data was a PH model
with no interior knots. Explanatory variables significant in a multivari-
able flexible parametric PH model were as for the Cox regression
model. With the exception of pimobendan administration, all signifi-
cant variables were included in the parametric PH model. In agree-
ment with the Cox regression model, a time-dependent effect for
NT-proBNP was identified in the flexible parametric model (P < .001;
Table 3). Figure 1 presents model predictions for the percentage of
dogs not reaching the composite endpoint within 1 year for each com-
bination of prognostic variables. Based on the values of explanatory
variables, a range of prognoses was predicted for different hypotheti-
cal patient profiles. For example, a hypothetical group of dogs with
DMVD that were not CKCSs, with moderate intensity heart murmurs,
heart rates <110 bpm, no cough, and NT-proBNP <900 pmol/L had a
low risk of disease progression; 93.7% (95% CI, 89.9%-96.0%) of dogs
with these characteristics were predicted not to start diuretics or die
because of their heart disease during the next 12 months. In contrast,
for a hypothetical group of CKCSs with heart murmurs and thrills,
heart rates >140 bpm, no cough, and NT-proBNP >1800 pmol/L, only
17.7% (95% CI, 4.6%-37.6%) were predicted not to reach these end-
points over the next 12 months.
4 | DISCUSSION
In our study, higher plasma NT-proBNP concentrations, heart rates
and heart murmur intensities, being a CKCS, presence of cough, and
receiving pimobendan were associated with a higher hazard of dogs
with presumed stage B DMVD progressing to initiation of treatment
with a potent diuretic or experiencing cardiac-related death.
4.1 | Cardiac biomarkers
A strong association was observed between plasma concentration of
NT-proBNP and clinical progression in dogs with presumed stage B
DMVD. This finding concurs with previous studies, which demon-
strated that higher circulating NT-proBNP concentration was associ-
ated with developing CHF in dogs with preclinical DMVD.3,4 In our
study, NT-proBNP concentration had a time-dependent effect,
whereby there was a weakening of the association with the outcome
over time ie, the hazard ratio between categories including dogs with
the highest [>1800 pmol/L] and lowest [<900 pmol/L] NT-proBNP con-
centrations decreased over time after sampling. This finding suggests
that the biomarker provides the most useful information regarding
prognosis in the initial months after sampling in dogs with preclinical
DMVD, with less ability to predict outcome later on, thereby supporting
the recommendation of serial sampling of individuals.20–22
TABLE 2 Multivariable Cox regression model for variables associated
with dogs with presumed stage B degenerative mitral valve disease
(DMVD) reaching a composite endpoint of initiation of a potent
diuretic or cardiac-related death. A time-dependent effect for plasma
N-terminal pro B-type natriuretic peptide (NT-proBNP)
(>1800 pmol/L versus <900 pmol/L) is included. Observations for
614 individuals
Variable Category Hazard ratio (95% CI) P value
NT-proBNP
(pmol/L)
<900 Baseline <.001
900-1800 1.83 (1.17-2.87)
>1800 10.60 (5.41-20.75)
Cough No Baseline .004
Yes 1.75 (1.21-2.53)
Heart rate (bpm) Continuous 1.013a (1.005-1.021) .002
Murmur
intensity
Soft (grade I/II) Baseline <.001
Moderate (III) 2.23 (1.32-3.76)
Loud (IV) 2.76 (1.60-4.78)
Thrilling (V/VI) 4.01 (2.14-7.50)
CKCS No Baseline .009
Yes 1.60 (1.12-2.27)
Pimobendan No Baseline .001
Yes 2.43 (1.50-3.94)
Time-dependent
effect
NT-proBNP
>1800 pmol/L
versus
<900 pmol/L
−0.12b (−0.17 to
−0.05)
<.001
Abbreviations: bpm, beats per minute; CI, confidence interval; CKCS, Cav-
alier King Charles Spaniel.
a Increase in hazard ratio per heartbeat per minute.
b log (HR) for the highest versus lowest levels of NT-proBNP decreased by
0.12 for each unit increase in time (month).
TABLE 3 Multivariable flexible parametric proportional hazards
model for variables associated with dogs with presumed stage B
degenerative mitral valve disease (DMVD) reaching a composite
endpoint of initiation of a potent diuretic or cardiac-related death. A
time-dependent effect for plasma N-terminal pro B-type natriuretic
peptide (NT-proBNP) (>1800 pmol/L versus <900 pmol/L) is
included. Observations for 614 individuals
Variable Category
Hazard ratio
(95% CI) P value
NT-proBNP (pmol/L) <900 Baseline <.001
900-1800 1.76 (1.12-2.77)
>1800 5.41 (3.47-8.41)
Cough No Baseline .005
Yes 1.72 (1.18-2.49)
Heart rate (bpm) <110 Baseline .02
110-140 1.35 (0.85-2.15)
>140 1.94 (1.18-3.20)
Murmur intensity Soft (grade I/II) Baseline <.001
Moderate (III) 2.38 (1.41-4.00)
Loud (IV) 2.70 (1.56-4.68)
Thrilling (V/VI) 4.45 (2.37-8.34)
CKCS No Baseline .01
Yes 1.54 (1.08-2.19)
Time-dependent
effect NT-proBNP
>1800 pmol/L versus <900 pmol/L <.001
Abbreviations: bpm, beats per minute; CI, confidence interval; CKCS, Cav-
alier King Charles Spaniel.
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Although marginal evidence was found for an association
between plasma cTnI concentration and clinical progression in the uni-
variable analysis, insufficient evidence was found for an association in
the multivariable analysis. In contrast, previous studies identified
strong associations between cTnI and mortality in cohorts including
dogs with CHF caused by DMVD.10,21,23 The subset of dogs in our
study was likely to represent a group with less severe cardiac disease
(on average) than cohorts that also included dogs prescribed CHF
treatment. Serial measurements of cTnI disclosed an increase in this
biomarker within the 6 months preceding death in dogs that died
because of their cardiac disease,21 highlighting that cTnI is increased
in the most advanced stages of DMVD. Because cTnI is not a specific
biomarker for cardiac disease, the increase in this marker in presumed
stage B dogs was possibly more likely to be a result of noncardiac
causes than advanced cardiac disease, thus explaining a lack of associ-
ation between cTnI and DMVD clinical progression in our study.
4.2 | Presenting signs, clinical findings, and
signalment
Having a higher heart rate was associated with an increased hazard of
presumed stage B dogs progressing to initiation of potent diuretic treat-
ment or cardiac-related death. This finding concurs with previous studies
that observed associations between increased heart rate and adverse
cardiac outcome in dogs with preclinical DMVD.2,6 Moreover, studies
evaluating the prognostic value of heart rate in dogs with a wider range
of DMVD severity (including those diagnosed with CHF)10,21,24,25
reported that having a higher heart rate was associated with an
increased hazard of adverse outcome. Although having an increased
heart rate is associated with more advanced DMVD,26 this finding is not
specific for cardiac disease and can be influenced by a number of factors
including emotional state and noncardiac disease.27–29
In our study, dogs with heart murmur intensities grade III or above
had a higher hazard of clinical progression than those with softer mur-
murs. This observation concurs with the findings of a randomized con-
trolled trial that observed an association between higher heart murmur
intensity and shorter time until developing CHF in CKCSs with preclini-
cal DMVD.7 In agreement, another study reported that CKCSs with
heart murmur intensities ≥III/VI had an increased hazard of developing
CHF than did those with lower intensity murmurs.6 Moreover, heart
murmur intensity has been found to correlate with DMVD disease
severity30,31 and was associated with cardiac-related death in another
cohort of dogs with DMVD attending a UK research clinic.32 Dogs with
higher intensity murmurs in our study thus might represent dogs with
more advanced preclinical DMVD that were more likely to subse-
quently receive potent diuretics or die of their heart disease. Although
descriptors of heart murmur intensity grades were provided on data
collection forms, grading heart murmur intensity is subjective and can
be influenced by factors such as body condition, emotional state, and
how easy a dog is to auscultate.33 Our study evaluated heart murmur
intensity measured on a single occasion for each dog, thus analyses of
intraobserver and interobserver variation were not performed.
The presence of cough also was associated with increased hazard
of clinical progression. In agreement, a previous study reported an asso-
ciation between presence of cough at initial examination and subse-
quent progression of ACVIM-HD class in dogs with stage B DMVD.5
Coughing can be triggered by bronchial compression as a result of atrial
enlargement in more advanced preclinical DMVD, preceding the onset
of CHF.34 Alternatively, the observed association might have occurred
if veterinarians elected to start treatment with a potent diuretic
FIGURE 1 Risk estimates for the percentage of dogs with presumed stage B degenerative mitral valve disease (DMVD) not reaching the
composite endpoint (cardiac death or initiation of a potent diuretic) within 1 year for each combination of explanatory variables. The 95%
confidence intervals are presented in parentheses for dogs with the lowest and highest estimates for each table. CKCS, Cavalier King Charles
Spaniel; bpm, beats per minute
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because of the presence of a cough, without confirming the diagnosis
of CHF. A cough in a dog with a murmur is not considered sufficient
reason to start CHF treatment, and radiographic evaluation is recom-
mended to avoid inappropriate use of diuretics.1,13,34 However, only
71 (57.7%) dogs starting diuretic treatment had evidence that radiogra-
phy was undertaken, showing that veterinary practitioners frequently
prescribed diuretics without radiographic confirmation of CHF.
Cavalier King Charles Spaniels had a higher hazard of starting
diuretic treatment or experiencing cardiac-related death compared
with a category including all other breeds. This observation may be a
result of breed differences in disease progression. Alternatively,
knowledge of breed predispositions for DMVD might influence the
likelihood of dog owners seeking veterinary care or veterinarians pre-
scribing CHF treatment for symptomatic CKCSs compared to other
breeds showing similar clinical signs.
4.3 | Treatment
Pimobendan administration was associated with increased hazard of
reaching the composite endpoint in our study. Strong evidence indi-
cates that pimobendan is beneficial in extending survival in a subset
of dogs with advanced preclinical DMVD and cardiomegaly confirmed
by diagnostic imaging (ie, left atrial-to-aortic ratio ≥1.6, normalized left
ventricular internal diameter in diastole ≥1.7, and vertebral heart sum
>10.5).2 Results of our study were therefore likely to reflect that
pimobendan was more frequently prescribed to dogs with more
advanced stage B DMVD and a worse prognosis. Echocardiographic
and radiographic assessment of cardiac size currently is required to
determine whether a dog would benefit from pimobendan.2 This fac-
tor is reflected in our study, because exploratory analyses identified a
strong association between pimobendan administration and undergo-
ing diagnostic imaging in presumed stage B dogs (Chi squared test,
P < .001). Because we aimed to identify the predictive value of factors
not dependent on diagnostic imaging, pimobendan administration was
excluded from the flexible parametric model.
4.4 | General strengths and limitations
Our study used a prospective cohort design to provide further insights
into factors associated with disease progression in dogs with pre-
sumed stage B DMVD. Several clinical measurements identified in our
study (NT-proBNP, heart rate, and heart murmur intensity) also were
predictive of mortality in cohorts of dogs with different stages of
DMVD,10,21,25,32,35 supporting the prognostic value of these measure-
ments. Some prognostic factors in our study might reflect changes
occurring earlier in the clinical course of the disease, whereas prog-
nostic factors associated with mortality in heterogeneous cohorts (but
not with clinical progression in presumed stage B dogs) might reflect
changes occurring during the later stages of DMVD. For example,
a strong association was found between plasma NT-proBNP
concentration and clinical progression in presumed stage B dogs, but a
significant association between cTnI and this outcome was not
observed. Conversely, associations between both biomarkers and
mortality have been reported for cohorts including dogs with CHF
because of DMVD.10,21,23 This is consistent with the findings of
another study, in which NT-proBNP measurements increased at an
earlier stage in the natural progression of the disease than did circulat-
ing cTnI.21
The predictions derived from the flexible parametric model high-
light that using information from a number of factors is more informa-
tive when forming a prognosis than measuring a single factor. The
prognostic factors identified in our study, therefore, should be evalu-
ated in combination rather than in isolation. Risk stratification based
on disease severity could facilitate decision-making and advice to
owners when managing dogs with DMVD in practice.2,21 For example,
dogs identified as having more advanced presumed stage B DMVD
might receive the greatest benefit from further diagnostic investiga-
tions and subsequent treatment, whereas a “watch and wait”
approach might be more appropriate for a dog belonging to a low risk
group. In addition, dogs predicted to have a high risk of clinical pro-
gression might benefit from more vigilant monitoring (eg, measuring
sleeping respiratory rate). Although risk can be estimated based on
the values of factors identified in our study (eg, the percentage of
dogs with those values not reaching the composite endpoint within
12 months), it is not possible to say whether an individual dog will
reach the composite endpoint and uncertainty will remain in the prog-
nosis for an individual dog.
Our study analyzed data from a large cohort of dogs attending
73 primary care practices located across the United Kingdom. How-
ever, it is unclear whether this sample of dogs was representative of
all dogs with DMVD attending UK primary care practices. For exam-
ple, clinicians might have more confidence making a presumptive diag-
nosis of DMVD in dogs of certain breeds that have presented with
heart murmurs typical of mitral regurgitation because of preconceived
knowledge of breed predispositions. Furthermore, the results of our
study might not be generalizable to populations of dogs with pre-
sumed DMVD in other geographical locations.
To allow the results of our study to be applied to settings in which
diagnostic imaging is not routinely performed, echocardiographic con-
firmation of the presumptive DMVD diagnosis was not an inclusion
criterion. It is therefore possible that dogs erroneously diagnosed with
DMVD were included in our study. However, participating clinicians
were provided with information on typical presentation and risk fac-
tors for DMVD to improve the accuracy of presumptive diagnoses
and recruited cases largely consisted of small to medium-sized older
dogs, a population known to have a high prevalence of DMVD.36,37
Moreover, the breed, body weight, and age distributions of the dogs
in our study were similar to those reported in previous studies
restricted to dogs with DMVD confirmed by echocardiography.21,32
Our study included dogs that were not receiving potent diuretics at
recruitment and that were assumed to have stage B DMVD, defined
as “patients with structural heart disease (e.g. the typical murmur of
mitral valve regurgitation is present), but that have never developed
clinical signs caused by heart failure.”1 Because potent diuretics are
essential for dogs with CHF,1 it is unlikely that dogs included in our
study had stage C or D DMVD at recruitment. However, the rationale
behind prescribing diuretics was not explored and some dogs without
CHF may have been inappropriately prescribed diuretics and excluded
from the study.
MATTIN ET AL. 7
Misclassification or measurement error of explanatory variables
also was possible, and evaluating physical examination findings and
the presence or absence of clinical signs is inherently subjective. One
measurement for each explanatory variable, recorded at recruitment,
was used in our study. However, some variables, such as plasma bio-
marker concentrations, might have changed over time (time-varying
risk factors). An alternative approach would have been to record serial
measurements of explanatory variables and to develop a Cox regres-
sion model including time-varying covariates.38 However, there might
be practical difficulties associated with collecting multiple measure-
ments of variables at specified time points. Another limitation of our
study is that selection bias might have arisen because of censoring
and missing data. Right-censored dogs may have had different out-
comes than those with more complete follow-up. Complete case anal-
ysis was used in the multivariable models (dogs with missing data for
any of the final model variables were excluded), and thus bias might
have been introduced if data were not missing randomly.14
In addition, limitations relating to the outcome of interest should
be borne in mind when interpreting our results. The majority of pre-
sumed stage B dogs reaching an endpoint started treatment with a
potent diuretic, rather than dying of their heart disease without initia-
tion of diuretic treatment. It is unclear whether the composite end-
point was a reliable proxy for advancing disease severity, and it is
possible that some explanatory variables (eg, presence of cough or
loud heart murmur) were the reason that veterinarians started treat-
ment with diuretics, rather than being predictive of future onset of
CHF or cardiac death. This possibility could have resulted in differen-
tial misclassification and an overestimate in the measure of associa-
tion. However, dogs starting diuretics within 14 days of recruitment
were excluded, thereby limiting misclassification bias associated with
clinicians initiating diuretic treatment because of clinical findings at
the initial visit. Although guidelines for the management of DMVD
recommend performing thoracic radiography to diagnose CHF,1 this
procedure was not consistently undertaken before initiating diuretic
treatment, and starting treatment with a potent diuretic was based on
the clinicians' perceptions of heart disease progression in many cases.
Radiographic confirmation of CHF would have improved the validity
of the results, but the lack of these data reflects the reality of primary
care practice. Another UK study also reported that diagnostic imaging
was not undertaken often when evaluating dogs with suspected CHF
in primary care practice.39 It is unclear why thoracic radiography was
not performed more frequently in these cases, and future research
exploring clinical decision making when managing dogs with DMVD
and the reliability of CHF diagnoses in primary care practice is war-
ranted. Factors that may deter clinicians from performing thoracic
radiographs might include owner inability to pay for diagnostic tests
and a reluctance to sedate uncooperative patients for radiography in a
country where manual restraint for radiography is discouraged. Finally,
relevant treatment data might not be captured in EPRs if owners
obtained diuretics from online pharmacies or other veterinary prac-
tices. However, despite limitations relating to the outcome, several
key findings were consistent with those reported in previous studies
that used radiography to assess clinical progression in dogs with pre-
clinical DMVD.2–4,6,7
Our results cannot be used to differentiate stages B1 and B2
DMVD, or be used to make treatment recommendations. However, it
might be possible to develop a scoring system based on variables
obtained from routine history, physical examination, and cardiac bio-
marker concentrations to help distinguish between the preclinical
stages of DMVD and even potentially select animals that are most
likely to benefit from treatment.40 The prognostic variables identified
in our study, that are likely to reflect more advanced disease, could be
worthy candidates to evaluate in such work.
As described above, it is unclear whether the evaluated compos-
ite endpoint was a reliable proxy for advancing DMVD. The observed
associations between explanatory variables and the outcome could
have arisen if veterinarians elected to start treatment with a potent
diuretic because of preconceptions relating to breed predispositions,
historical, or physical examination findings (eg, the presence of cough
and high intensity murmur), rather than these factors being predictive
of future disease progression. Validation of the prognostic model in a
different population would therefore be of value,17 particularly if dis-
ease progression was supported by diagnostic imaging in an indepen-
dent test set.
In conclusion, data obtained from taking a history and performing
a physical examination could be used in combination with NT-proBNP
concentrations to risk stratify dogs with presumed stage B DMVD
managed by primary care practitioners. Dogs identified as having a
high risk of disease progression might benefit from more frequent
monitoring, further diagnostic evaluation, or referral to a veterinary
cardiologist.
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